Angiotensin-Converting Enzyme Inhibitors

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Also Known As:

ACE Inhibitors; Angiotensin I-Converting Enzyme Inhibitors; Angiotensin-Converting Enzyme Antagonists; Antagonists, Angiotensin-Converting Enzyme; Antagonists, Kininase II; Inhibitors, ACE; Inhibitors, Angiotensin-Converting Enzyme; Inhibitors, Kininase II; Kininase II Antagonists; Angiotensin Converting Enzyme Antagonists; Angiotensin Converting Enzyme Inhibitors; Angiotensin I Converting Enzyme Inhibitor; Angiotensin I Converting Enzyme Inhibitors; Antagonists, Angiotensin Converting Enzyme; Enzyme Antagonists, Angiotensin-Converting; Enzyme Inhibitor, Angiotensin-Converting; Enzyme Inhibitors, Angiotensin-Converting; II Inhibitor, Kininase; Inhibitor, ACE; Inhibitor, Angiotensin-Converting Enzyme; Inhibitor, Kininase II; Inhibitors, Angiotensin Converting Enzyme; ACE Inhibitor; Angiotensin Converting Enzyme Inhibitor; Angiotensin I-Converting Enzyme Inhibitor; Angiotensin-Converting Enzyme Inhibitor; Kininase II Inhibitor; Kininase II Inhibitors

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Protease Inhibitors: 6291
        Angiotensin-Converting Enzyme Inhibitors: 17791

E P Havranek Selected Research

E P Havranek Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure